
FDA Okays AI-based Prostate Cancer Risk-Stratification Tool
The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with nonmetastatic prostate cancer. The authorization means the …